Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Tuan Phan

General Practice Santa Ana, CA Medical Doctor

NPI 1477988004 CMS profile 293589

1405 N Bristol St, Santa Ana, CA 92706

Open in the dashboard

General payments

$4,579

42 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Tuan Phan of Santa Ana, CA is reported in the CMS Open Payments database as having received $4,579 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,132 10
2022 General $692 7
2021 General $100 1
2020 General $251 2
2019 General $2,405 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tuan Phan
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Tuan Phan were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Tuan Phan General Practice median Middle half National median
2019 $2,405 $107 $37–$285 $163
2020 $251 $75 $25–$213 $114
2021 $100 $93 $30–$272 $132
2022 $692 $103 $36–$279 $149
2023 $1,132 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Gilead Sciences, Inc. $1,762 15 payments
  2. AstraZeneca Pharmaceuticals LP $1,513 13 payments
  3. Amarin Pharma Inc. $385 3 payments
  4. Theratechnologies Inc. $125 1 payment
  5. Pfizer Inc. $125 1 payment
  6. Regeneron Healthcare Solutions, Inc. $122 1 payment
  7. Novo Nordisk Inc $119 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $113 1 payment
  9. Janssen Pharmaceuticals, Inc $107 1 payment
  10. Lilly USA, LLC $93 2 payments
  11. Other $117 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,579 42 payments
Products named General payments · program years 2019–2023
  1. Vemlidy $1,402 12 payments
  2. FARXIGA $913 8 payments
  3. Vascepa $385 3 payments
  4. BREZTRI $241 2 payments
  5. TROGARZO $125 1 payment
  6. FASENRA $125 1 payment
  7. Epclusa $125 1 payment
  8. EUCRISA $125 1 payment
  9. BRILINTA $124 1 payment
  10. PRALUENT $122 1 payment
  11. Other $561 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record